-+ 0.00%
-+ 0.00%
-+ 0.00%

Eupraxia reports EP-104GI RESOLVE trial EoEHSS subscore improvements in eosinophilic esophagitis

PUBT·05/06/2026 11:09:20
Listen to the news
Eupraxia reports EP-104GI RESOLVE trial EoEHSS subscore improvements in eosinophilic esophagitis
  • Eupraxia released first EoE Histology Scoring System sub-score results from ongoing Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis, with data already presented at Digestive Disease Week in Chicago.
  • Histology sub-scores indicated broad improvements in measures of tissue inflammation across reported cohorts, with improvements in tissue architecture consistent with reduced fibrosis in most cohorts.
  • Highest dose cohort showed strongest overall response across both inflammation and fibrosis-related measures, supporting dose-response signal.
  • Phase 2b randomized, placebo-controlled portion of RESOLVE is recruiting 120 mg and 160 mg doses, with top-line results expected in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.